Dean Li

Dean Li, Head of R&D at Merck, discusses the groundbreaking results of Merck's oral PCSK9 candidate, enlicitide, which shows impressive LDL cholesterol reduction comparable to injectables. He explores the challenges of making effective heart disease treatments more accessible and the potential public health impact of wider adoption. The conversation also touches on FDA leadership changes and hopes for regulatory pathways that prioritize patient access while maintaining safety. Li emphasizes the importance of innovating beyond injectables and targeting new areas in cardiometabolic health.